Merck HCV NS3/4A-NS5A combo gains FDA 'breakthrough' status
This article was originally published in Scrip
Executive Summary
Merck has won the FDA's coveted breakthrough therapy designation for two of the company's compounds MK-5172 and MK-8742 as a combination therapy for chronic hepatitis C virus (HCV) infection.